Beam Therapeutics’ Sickle Cell Treatment Gets FDA’s Generative Medicine Advanced Therapy Designation MarketWatch Nawigacja wpisu Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease – Yahoo Finance UVA Health University Medical Center Earns National, State Breastfeeding Awards – UVA Health Newsroom
